Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Has results × mCRPC × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 96 Carcinoma, Non-Small-Cell Lung 52 Prostatic Neoplasms 51 Multiple Myeloma 43 Lymphoma 33 Leukemia, Lymphocytic, Chronic, B-Cell 31 Neoplasms 29 Neoplasm Metastasis 29 Leukemia, Myeloid, Acute 28 Ovarian Neoplasms 25 Melanoma 24 Lymphoma, Non-Hodgkin 24 Triple Negative Breast Neoplasms 23 Hematologic Neoplasms 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Lung Neoplasms 19 Fallopian Tube Neoplasms 18 Glioblastoma 16 Urinary Bladder Neoplasms 15 Myelodysplastic Syndromes 15 Lymphoma, Follicular 14 Hodgkin Disease 14 Sarcoma 13 Lymphoma, Mantle-Cell 13 Lymphoma, Large B-Cell, Diffuse 13 Leukemia 13 Colorectal Neoplasms 13 Carcinoma, Renal Cell 13 Small Cell Lung Carcinoma 12 Glioma 12

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡